Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

Corticotropin releasing hormone and imaging, rethinking the stress axis.

Contoreggi C.

Nucl Med Biol. 2015 Apr;42(4):323-39. doi: 10.1016/j.nucmedbio.2014.11.008. Epub 2014 Nov 26. Review.

2.

Mu Opioid Receptor Binding Correlates with Nicotine Dependence and Reward in Smokers.

Kuwabara H, Heishman SJ, Brasic JR, Contoreggi C, Cascella N, Mackowick KM, Taylor R, Rousset O, Willis W, Huestis MA, Concheiro M, Wand G, Wong DF, Volkow ND.

PLoS One. 2014 Dec 10;9(12):e113694. doi: 10.1371/journal.pone.0113694. eCollection 2014.

3.

Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study.

Lee MR, Wehring HJ, McMahon RP, Linthicum J, Cascella N, Liu F, Bellack A, Buchanan RW, Strauss GP, Contoreggi C, Kelly DL.

Schizophr Res. 2013 Apr;145(1-3):110-5. doi: 10.1016/j.schres.2013.01.001. Epub 2013 Feb 13.

4.

Addiction and corticotropin-releasing hormone type 1 receptor antagonist medications.

Contoreggi C, Lee MR, Chrousos G.

Ann N Y Acad Sci. 2013 Apr;1282:107-18. doi: 10.1111/nyas.12007. Epub 2013 Feb 11. Review.

PMID:
23398379
5.

[(76) Br]BMK-152, a nonpeptide analogue, with high affinity and low nonspecific binding for the corticotropin-releasing factor type 1 receptor.

Jagoda EM, Lang L, McCullough K, Contoreggi C, Kim BM, Ma Y, Rice KC, Szajek LP, Eckelman WC, Kiesewetter DO.

Synapse. 2011 Sep;65(9):910-8. doi: 10.1002/syn.20919. Epub 2011 Apr 11.

6.

Pharmacy informatics in controlled substances research.

Lin JL, Vahabzadeh M, Mezghanni M, Na PJ, Leff M, Contoreggi C.

AMIA Annu Symp Proc. 2008 Nov 6:1025.

PMID:
18998973
7.

Molecular genetics of addiction and related heritable phenotypes: genome-wide association approaches identify "connectivity constellation" and drug target genes with pleiotropic effects.

Uhl GR, Drgon T, Johnson C, Li CY, Contoreggi C, Hess J, Naiman D, Liu QR.

Ann N Y Acad Sci. 2008 Oct;1141:318-81. doi: 10.1196/annals.1441.018. Review.

8.

Bromocriptine administration reduces hyperphagia and adiposity and differentially affects dopamine D2 receptor and transporter binding in leptin-receptor-deficient Zucker rats and rats with diet-induced obesity.

Davis LM, Michaelides M, Cheskin LJ, Moran TH, Aja S, Watkins PA, Pei Z, Contoreggi C, McCullough K, Hope B, Wang GJ, Volkow ND, Thanos PK.

Neuroendocrinology. 2009;89(2):152-62. doi: 10.1159/000170586. Epub 2008 Nov 4.

9.

Greater nicotinic acetylcholine receptor density in smokers than in nonsmokers: a PET study with 2-18F-FA-85380.

Mukhin AG, Kimes AS, Chefer SI, Matochik JA, Contoreggi CS, Horti AG, Vaupel DB, Pavlova O, Stein EA.

J Nucl Med. 2008 Oct;49(10):1628-35. doi: 10.2967/jnumed.108.050716. Epub 2008 Sep 15.

10.

A clinical recruiting management system for complex multi-site clinical trials using qualification decision support systems.

Vahabzadeh M, Lin JL, Mezghanni M, Contoreggi C, Leff M.

AMIA Annu Symp Proc. 2007 Oct 11:1141.

PMID:
18694237
11.

Heavy marijuana users show increased serum apolipoprotein C-III levels: evidence from proteomic analyses.

Jayanthi S, Buie S, Moore S, Herning RI, Better W, Wilson NM, Contoreggi C, Cadet JL.

Mol Psychiatry. 2010 Jan;15(1):101-12. doi: 10.1038/mp.2008.50. Epub 2008 May 13.

12.

Integration of in vivo and in vitro approaches to characterize the toxicity of Antalarmin, a corticotropin-releasing hormone receptor antagonist.

Horn TL, Harder JB, Johnson WD, Curry PT, Parchment RE, Morrissey RL, Mellick PW, Calis KA, Gold PW, Rice KC, Contoreggi C, Charney DS, Cizza G, Glaze ER, Tomaszewski JE, McCormick DL.

Toxicology. 2008 Jun 3;248(1):8-17. doi: 10.1016/j.tox.2008.03.002. Epub 2008 Mar 13.

13.

Quantification of nicotinic acetylcholine receptors in the human brain with PET: bolus plus infusion administration of 2-[18F]F-A85380.

Kimes AS, Chefer SI, Matochik JA, Contoreggi CS, Vaupel DB, Stein EA, Mukhin AG.

Neuroimage. 2008 Jan 15;39(2):717-27. Epub 2007 Sep 19.

14.

"Higher order" addiction molecular genetics: convergent data from genome-wide association in humans and mice.

Uhl GR, Drgon T, Johnson C, Fatusin OO, Liu QR, Contoreggi C, Li CY, Buck K, Crabbe J.

Biochem Pharmacol. 2008 Jan 1;75(1):98-111. Epub 2007 Jul 25. Review.

15.

Cerebral metabolism and mood in remitted opiate dependence.

Galynker II, Eisenberg D, Matochik JA, Gertmenian-King E, Cohen L, Kimes AS, Contoreggi C, Kurian V, Ernst M, Rosenthal RN, Prosser J, London ED.

Drug Alcohol Depend. 2007 Oct 8;90(2-3):166-74. Epub 2007 May 22.

16.

Increased occupancy of dopamine receptors in human striatum during cue-elicited cocaine craving.

Wong DF, Kuwabara H, Schretlen DJ, Bonson KR, Zhou Y, Nandi A, Brasić JR, Kimes AS, Maris MA, Kumar A, Contoreggi C, Links J, Ernst M, Rousset O, Zukin S, Grace AA, Lee JS, Rohde C, Jasinski DR, Gjedde A, London ED.

Neuropsychopharmacology. 2006 Dec;31(12):2716-27. Epub 2006 Sep 13. Erratum in: Neuropsychopharmacology. 2007 Jan;32(1):256. Lee, Jae Sung [added].

17.

Bromocriptine reduces steatosis in obese rodent models.

Davis LM, Pei Z, Trush MA, Cheskin LJ, Contoreggi C, McCullough K, Watkins PA, Moran TH.

J Hepatol. 2006 Sep;45(3):439-44. Epub 2006 May 6.

PMID:
16780999
18.

Development of 5-HT1A receptor radioligands to determine receptor density and changes in endogenous 5-HT.

Jagoda EM, Lang L, Tokugawa J, Simmons A, Ma Y, Contoreggi C, Kiesewetter D, Eckelman WC.

Synapse. 2006 May;59(6):330-41.

PMID:
16440292
19.

Effect of rate of administration on subjective and physiological effects of intravenous cocaine in humans.

Nelson RA, Boyd SJ, Ziegelstein RC, Herning R, Cadet JL, Henningfield JE, Schuster CR, Contoreggi C, Gorelick DA.

Drug Alcohol Depend. 2006 Mar 15;82(1):19-24. Epub 2005 Sep 6.

PMID:
16144747
20.

Influence of psychotherapy attendance on buprenorphine treatment outcome.

Montoya ID, Schroeder JR, Preston KL, Covi L, Umbricht A, Contoreggi C, Fudala PJ, Johnson RE, Gorelick DA.

J Subst Abuse Treat. 2005 Apr;28(3):247-54.

21.

Risky decision making and the anterior cingulate cortex in abstinent drug abusers and nonusers.

Fishbein DH, Eldreth DL, Hyde C, Matochik JA, London ED, Contoreggi C, Kurian V, Kimes AS, Breeden A, Grant S.

Brain Res Cogn Brain Res. 2005 Apr;23(1):119-36.

PMID:
15795139
22.

Prefrontal cortical dysfunction in abstinent cocaine abusers.

Bolla K, Ernst M, Kiehl K, Mouratidis M, Eldreth D, Contoreggi C, Matochik J, Kurian V, Cadet J, Kimes A, Funderburk F, London E.

J Neuropsychiatry Clin Neurosci. 2004 Fall;16(4):456-64.

23.

Nonpeptide corticotropin-releasing hormone receptor type 1 antagonists and their applications in psychosomatic disorders.

Contoreggi C, Rice KC, Chrousos G.

Neuroendocrinology. 2004;80(2):111-23. Epub 2004 Oct 27. Review.

PMID:
15523186
24.

New tools to monitor stress using non-invasive PET imaging.

Eckelman WC, Rice KC, Contoreggi C.

Ann N Y Acad Sci. 2004 Jun;1018:487-94.

PMID:
15240406
25.

Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence.

Montoya ID, Gorelick DA, Preston KL, Schroeder JR, Umbricht A, Cheskin LJ, Lange WR, Contoreggi C, Johnson RE, Fudala PJ.

Clin Pharmacol Ther. 2004 Jan;75(1):34-48.

26.

Stress hormone responses to corticotropin-releasing hormone in substance abusers without severe comorbid psychiatric disease.

Contoreggi C, Herning RI, Na P, Gold PW, Chrousos G, Negro PJ, Better W, Cadet JL.

Biol Psychiatry. 2003 Nov 1;54(9):873-8.

PMID:
14573313
27.

Treatment-seeking inpatient cocaine abusers show hypothalamic dysregulation of both basal prolactin and cortisol secretion.

Contoreggi C, Herning RI, Koeppl B, Simpson PM, Negro PJ Jr, Fortner-Burton C, Hess J.

Neuroendocrinology. 2003 Sep;78(3):154-62.

PMID:
14512708
28.

Autoradiographic visualization of corticotropin releasing hormone type 1 receptors with a nonpeptide ligand: synthesis of [(76)Br]MJL-1-109-2.

Jagoda E, Contoreggi C, Lee MJ, Kao CH, Szajek LP, Listwak S, Gold P, Chrousos G, Greiner E, Kim BM, Jacobson AE, Rice KC, Eckelman W.

J Med Chem. 2003 Aug 14;46(17):3559-62.

PMID:
12904058
29.

Orbitofrontal cortex dysfunction in abstinent cocaine abusers performing a decision-making task.

Bolla KI, Eldreth DA, London ED, Kiehl KA, Mouratidis M, Contoreggi C, Matochik JA, Kurian V, Cadet JL, Kimes AS, Funderburk FR, Ernst M.

Neuroimage. 2003 Jul;19(3):1085-94.

30.

Neural substrates of decision making in adults with attention deficit hyperactivity disorder.

Ernst M, Kimes AS, London ED, Matochik JA, Eldreth D, Tata S, Contoreggi C, Leff M, Bolla K.

Am J Psychiatry. 2003 Jun;160(6):1061-70.

PMID:
12777263
31.

2-[18F]F-A-85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans.

Kimes AS, Horti AG, London ED, Chefer SI, Contoreggi C, Ernst M, Friello P, Koren AO, Kurian V, Matochik JA, Pavlova O, Vaupel DB, Mukhin AG.

FASEB J. 2003 Jul;17(10):1331-3. Epub 2003 May 20.

PMID:
12759330
32.

Decision making in adolescents with behavior disorders and adults with substance abuse.

Ernst M, Grant SJ, London ED, Contoreggi CS, Kimes AS, Spurgeon L.

Am J Psychiatry. 2003 Jan;160(1):33-40.

PMID:
12505799
33.

Corticotropin releasing hormone (CRH) antagonist attenuates adjuvant induced arthritis: role of CRH in peripheral inflammation.

Webster EL, Barrientos RM, Contoreggi C, Isaac MG, Ligier S, Gabry KE, Chrousos GP, McCarthy EF, Rice KC, Gold PW, Sternberg EM.

J Rheumatol. 2002 Jun;29(6):1252-61.

PMID:
12064844
34.

Decision-making in a risk-taking task: a PET study.

Ernst M, Bolla K, Mouratidis M, Contoreggi C, Matochik JA, Kurian V, Cadet JL, Kimes AS, London ED.

Neuropsychopharmacology. 2002 May;26(5):682-91.

35.

Neural systems and cue-induced cocaine craving.

Bonson KR, Grant SJ, Contoreggi CS, Links JM, Metcalfe J, Weyl HL, Kurian V, Ernst M, London ED.

Neuropsychopharmacology. 2002 Mar;26(3):376-86.

36.

CRHR1 Receptor binding and lipophilicity of pyrrolopyrimidines, potential nonpeptide corticotropin-releasing hormone type 1 receptor antagonists.

Hsin LW, Tian X, Webster EL, Coop A, Caldwell TM, Jacobson AE, Chrousos GP, Gold PW, Habib KE, Ayala A, Eckelman WC, Contoreggi C, Rice KC.

Bioorg Med Chem. 2002 Jan;10(1):175-83.

PMID:
11738619
37.

Effects of triazolam on brain activity during episodic memory encoding: a PET study.

Mintzer MZ, Griffiths RR, Contoreggi C, Kimes AS, London ED, Ernst M.

Neuropsychopharmacology. 2001 Nov;25(5):744-56.

38.

The development of a potential single photon emission computed tomography (SPECT) imaging agent for the corticotropin-releasing hormone receptor type.

Tian X, Hsin LW, Webster EL, Contoreggi C, Chrousos GP, Gold PW, Habib K, Ayala A, Eckelman WC, Jacobson AE, Rice KC.

Bioorg Med Chem Lett. 2001 Feb 12;11(3):331-3.

PMID:
11212103
39.

Drug abusers show impaired performance in a laboratory test of decision making.

Grant S, Contoreggi C, London ED.

Neuropsychologia. 2000;38(8):1180-7.

PMID:
10838152
40.

Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates.

Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, Listwak S, Webster EL, Atkinson AJ, Schulkin J, Contoreggi C, Chrousos GP, McCann SM, Suomi SJ, Higley JD, Gold PW.

Proc Natl Acad Sci U S A. 2000 May 23;97(11):6079-84.

41.
42.

Effects of varying concentrations of bleach on in vitro HIV-1 replication and the relevance to injection drug use.

Contoreggi C, Jones S, Simpson P, Lange WR, Meyer WA 3rd.

Intervirology. 2000;43(1):1-5.

PMID:
10773730
43.

Prescription medications: a modifiable contributor to obesity.

Cheskin LJ, Bartlett SJ, Zayas R, Twilley CH, Allison DB, Contoreggi C.

South Med J. 1999 Sep;92(9):898-904. Review.

PMID:
10498166
44.

Ventilation-perfusion scintigraphic evaluation of pulmonary clot burden after percutaneous thrombolysis of clotted hemodialysis access grafts.

Petronis JD, Regan F, Briefel G, Simpson PM, Hess JM, Contoreggi CS.

Am J Kidney Dis. 1999 Aug;34(2):207-11.

PMID:
10430963
45.

Current management of infectious complications in the injecting drug user.

Contoreggi C, Rexroad VE, Lange WR.

J Subst Abuse Treat. 1998 Mar-Apr;15(2):95-106. Review.

PMID:
9561947
46.

Evaluation of HIV1 infection status by HIV1 PCR and culture methodologies in a small cohort of intravenous drug users.

Contoreggi CS, Jones SW, Lange WR, Meyer WA 3rd.

Res Virol. 1997 May-Jun;148(3):215-24.

PMID:
9201812
47.

Activation of memory circuits during cue-elicited cocaine craving.

Grant S, London ED, Newlin DB, Villemagne VL, Liu X, Contoreggi C, Phillips RL, Kimes AS, Margolin A.

Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):12040-5.

48.

Increasing opiate abstinence through voucher-based reinforcement therapy.

Silverman K, Wong CJ, Higgins ST, Brooner RK, Montoya ID, Contoreggi C, Umbricht-Schneiter A, Schuster CR, Preston KL.

Drug Alcohol Depend. 1996 Jun;41(2):157-65.

PMID:
8809505
49.

No evidence for chloroquine-associated retinopathy among missionaries on long-term malaria chemoprophylaxis.

Lange WR, Frankenfield DL, Moriarty-Sheehan M, Contoreggi CS, Frame JD.

Am J Trop Med Hyg. 1994 Oct;51(4):389-92.

PMID:
7943562
50.

Plasma levels of estradiol, testosterone, and DHEAS do not predict risk of coronary artery disease in men.

Contoreggi CS, Blackman MR, Andres R, Muller DC, Lakatta EG, Fleg JL, Harman SM.

J Androl. 1990 Sep-Oct;11(5):460-70.

Supplemental Content

Loading ...
Support Center